Tyvaso Inhaled denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for tyvaso inhaled are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Tyvaso Inhaled as Experimental

Cigna may classify Tyvaso (inhaled treprostinil) as experimental or investigational for a specific patient population or clinical indication when its internal coverage policy has not yet recognized that use as established. While Tyvaso carries FDA approval for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), denials under the experimental label most often arise when the requested use falls outside the population or functional-class criteria defined in Cigna's coverage policy — for example, earlier functional class than the policy covers, or a clinical scenario that Cigna has not yet reviewed against current evidence.

This denial is worth contesting because FDA approval and guideline support from major societies (including applicable CHEST, AHA/ACC, and ESC/ERS PAH guidelines) provide a strong evidentiary foundation. The appeal must document that your specific clinical situation falls within a recognized, evidence-supported indication — not merely within the FDA label, but within the clinical context the policy requires.

## Federal Appeal Framework

Under ACA Section 2719, experimental denials are fully appealable through internal review and independent external review. External review is especially valuable for experimental denials because an accredited IRO applies current medical evidence standards rather than Cigna's internal policy alone. File your internal appeal within 180 days of the denial. Request external review within approximately 4 months of the final internal denial. If clinical deterioration is occurring, request expedited review — it is available and decisions are time-compressed. ERISA employer plans carry the same protections under Section 503.

## Concrete Appeal Steps

1. Obtain the full text of Cigna's coverage policy for Tyvaso/inhaled treprostinil and identify the specific language used to support the experimental finding. 2. Confirm the FDA-approved indication(s) for the specific Tyvaso formulation being requested, and verify whether your clinical indication falls within them. 3. Have your pulmonologist prepare a letter that directly addresses each element of the experimental criteria. 4. Compile current guideline and regulatory documentation supporting the use for your specific diagnosis and functional status. 5. File internally and escalate to external review without delay if denied again.

## Documentation to Gather

• Diagnosis confirmation: Confirmed PAH or PH-ILD diagnosis with supporting right heart catheterization data, PFT results, and current functional classification.
• FDA indication documentation: The FDA prescribing information for the specific Tyvaso formulation, confirming the approved indication.
• Guideline support: Applicable CHEST, AHA/ACC, or ESC/ERS PAH/PH-ILD guideline recommendation for inhaled treprostinil at your diagnosis and functional class — your pulmonologist should confirm your case meets those criteria.
• Functional and hemodynamic assessments: Six-minute walk test, functional class assessments, and hemodynamic data with dates, demonstrating the clinical severity and treatment-goal gap.
• Pulmonologist medical-necessity letter: Addresses each experimental criterion directly, citing current evidence and your specific clinical situation.

## Criteria-Mapping Structure

List every element of Cigna's experimental/investigational definition as applied to Tyvaso. For each element, provide the corresponding documentation: FDA authorization, guideline recommendation, and clinical chart fact. Pay particular attention to any population-restriction language in the policy — map your diagnosis, functional class, and prior therapy history to each restriction to demonstrate that your case falls within a recognized, supported indication.